Prothena Corporation plc (PRTA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen, and welcome to the Procena Biosciences fourth quarter and full year 2025 Financial Results Conference Call. My name is Jeanne, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session at the end of today's call. If at any time during the call you require assistance, please press star followed by zero, and a coordinator will be happy to assist you. I would now like to turn the presentation over to Mark Johnson, Vice President and Head of Investor Relations at Prothena. Please proceed. Thank you, operator. Good afternoon, everyone, and welcome to today's call to review Prothena's business progress, fourth quarter and full year 2025 financial results, and 2026 financial guidance. Please review the press release we issued earlier today, which is available on our website at Prothena.com. and is also attached to a Form 8-K filed today with the SEC. In addition, we are using supplemental slides, which are available on our investor's website, events, and presentation section. On today's call, Dr. Gene Kinney, our President and Executive Officer, will provide opening remarks, including an overview on Prothena's corporate strategy. Chad Swanson, our Chief Development Officer, will provide an update on our ongoing partner clinical programs. And Phil Dolan, our vice president and head of discovery research, will provide an update on our active preclinical program. Tron Nguyen, our chief strategy officer and chief financial officer, will then discuss our 2025 financial results and 2026 financial guidance before turning it back to Jean for closing remarks, at which point we will open up the call for a Q&A session. Brandon Smith, our chief operating officer...